Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 276 participants.

Also called NCT01673204

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose screening
Phase
Phase 4
Enrolled
  • 276 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01673204
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
Not reported
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01673204. Randomized; double masking; primary purpose screening. Start 2012-10 (registry gives no type); primary completion 2014-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy
Condition
Diabetic Nephropathy
Intervention (Drug)
Calcitriol
Intervention (Drug)
Placebo
Lead sponsor
Seoul National University Hospital (class: other)

Record details

Record id
cardio:ct-nct01673204
Content hash
b9cffe2a468f653eda08fb4d679f5a70091725beeee149d81e9c2cf6171c5d67